• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by HOOKIPA Pharma Inc.

    2/14/25 12:26:29 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOOK alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    HOOKIPA Pharma Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    43906K209

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    43906K209


    1Names of Reporting Persons

    EcoR1 Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    388,861.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    388,861.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    388,861.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.0 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Percentage calculated based on 9,655,022 shares of Common Stock outstanding on November 11, 2024, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2024.


    SCHEDULE 13G

    CUSIP No.
    43906K209


    1Names of Reporting Persons

    Oleg Nodelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    388,861.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    388,861.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    388,861.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.0 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Percentage calculated based on 9,655,022 shares of Common Stock outstanding on November 11, 2024, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2024.


    SCHEDULE 13G

    CUSIP No.
    43906K209


    1Names of Reporting Persons

    EcoR1 Capital Fund Qualified, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    367,227.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    367,227.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    367,227.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Percentage calculated based on 9,655,022 shares of Common Stock outstanding on November 11, 2024, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    HOOKIPA Pharma Inc.
    (b)Address of issuer's principal executive offices:

    350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240 NEW YORK, NEW YORK 10118
    Item 2. 
    (a)Name of person filing:

    EcoR1 Capital, LLC, a Delaware limited liability company ("EcoR1") EcoR1 Capital Fund Qualified, L.P., a Delaware limited partnership ("Qualified Fund") Oleg Nodelman Qualified Fund is filing this statement jointly with the other reporting persons, but not as a member of a group, and it expressly disclaims membership in a group. In addition, the filing of this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any securities covered by this Schedule 13G. Each reporting person also disclaims beneficial ownership of the securities reported herein except to the extent of that person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    357 Tehama Street #3, San Francisco, CA 94103
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    43906K209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    EcoR1: 388,861 Qualified Fund: 367,227 Oleg Nodelman: 388,861
    (b)Percent of class:

    EcoR1: 4.0% Qualified Fund: 3.8% Oleg Nodelman: 4.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    EcoR1: 0 Qualified Fund: 0 Oleg Nodelman: 0

     (ii) Shared power to vote or to direct the vote:

    EcoR1: 388,861 Qualified Fund: 367,227 Oleg Nodelman: 388,861

     (iii) Sole power to dispose or to direct the disposition of:

    EcoR1: 0 Qualified Fund: 0 Oleg Nodelman: 0

     (iv) Shared power to dispose or to direct the disposition of:

    EcoR1: 388,861 Qualified Fund: 367,227 Oleg Nodelman: 388,861

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    EcoR1 Capital, LLC
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager
    Date:02/14/2025
     
    Oleg Nodelman
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Reporting person
    Date:02/14/2025
     
    EcoR1 Capital Fund Qualified, L.P.
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
    Date:02/14/2025
    Get the next $HOOK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOOK

    DatePrice TargetRatingAnalyst
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    12/2/2022Neutral → Underperform
    BofA Securities
    2/17/2022$15.00 → $8.00Buy
    HC Wainwright & Co.
    2/16/2022$3.00 → $4.00Outperform
    SVB Leerink
    11/12/2021$6.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2021$21.00 → $15.00Buy
    HC Wainwright & Co.
    11/10/2021$28.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $HOOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Peters Malte sold $20,684 worth of shares (25,172 units at $0.82), decreasing direct ownership by 32% to 54,347 units (SEC Form 4)

    4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

    10/9/25 4:22:11 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Peters Malte sold $26,842 worth of shares (29,176 units at $0.92), decreasing direct ownership by 27% to 79,519 units (SEC Form 4)

    4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

    7/23/25 6:09:44 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and CFO Coelho Mary Theresa sold $12,520 worth of shares (13,609 units at $0.92), decreasing direct ownership by 19% to 56,266 units (SEC Form 4)

    4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

    7/23/25 6:07:41 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOOK
    SEC Filings

    View All

    SEC Form 15-12G filed by HOOKIPA Pharma Inc.

    15-12G - HOOKIPA Pharma Inc. (0001760542) (Filer)

    8/8/25 12:48:05 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by HOOKIPA Pharma Inc.

    EFFECT - HOOKIPA Pharma Inc. (0001760542) (Filer)

    7/30/25 12:15:02 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by HOOKIPA Pharma Inc.

    EFFECT - HOOKIPA Pharma Inc. (0001760542) (Filer)

    7/30/25 12:15:05 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead

    NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA") today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and certain of its assets related to HOOKIPA's HB-500 program to Gilead Sciences, Inc. ("Gilead"). In connection with the consideration and evaluation of HOOKIPA's long-term prospects and strategies by HOOKIPA's board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement ("Asset Purchase Agreement") with Gilead pursuant to which Gilead agreed to acquire all of HOOKIPA's assets primarily related to or necessary for the conduct of HOOKIPA's HB-400 program, currently in clinica

    10/31/25 8:00:00 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

    NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA")), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to voluntarily delist from the Nasdaq Capital Market ("Nasdaq") and to deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and suspend its reporting obligations under Section 15(d) of the Exchange Act. In connection with the consideration and evaluation of HOOKIPA's long-term prospects and strategies by HOOKIPA's board of dire

    7/18/25 4:05:00 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV

    HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV) Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial Primary completion expected H2 2025 NEW YORK and VIENNA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that enrollment is complete in th

    1/30/25 7:00:00 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously

    12/20/24 7:37:05 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target

    RBC Capital Mkts reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $48.00 from $50.00 previously

    11/15/24 11:07:50 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma downgraded by BofA Securities

    BofA Securities downgraded HOOKIPA Pharma from Neutral to Underperform

    12/2/22 12:03:07 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOOK
    Leadership Updates

    Live Leadership Updates

    View All

    HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

    Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")

    11/14/24 4:05:00 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Announces Board of Directors Changes

    NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his o

    8/30/24 8:00:00 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

    New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 "AVALON-1" study with eseba-vec in Q4 2024 ASCO 2024 Presentation:   Reported best-in-class Phase 2 data for first-line HPV16+ head and neck cancer patients treated with eseba-vec (formerly HB-200) in combination with pembrolizumab during oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingRegulatory Progress:   Announced alignment with U.S. Food and Drug Administration (FDA) for the AVALON-1 Phase 2/3 pivotal trial design and protocol for eseba-vec, in combination with pembrolizumab for the first-li

    8/8/24 4:30:00 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOOK
    Financials

    Live finance-specific insights

    View All

    HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

    Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of careCompany will host a conference call at 4:15 p.m. ET today NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- H

    6/4/24 1:00:44 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

    Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:00 a.m. ET on Thursday, April 25, 2024, to highlight path to potential registration; participant details below NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDA

    4/25/24 7:01:00 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

    NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight o

    11/2/23 4:01:00 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    11/14/24 6:07:08 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    8/2/24 6:38:55 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by HOOKIPA Pharma Inc.

    SC 13G - HOOKIPA Pharma Inc. (0001760542) (Subject)

    7/8/24 6:51:26 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care